LMP7/TAP2 gene polymorphisms and HPV infection in esophageal carcinoma patients from a high incidence area in China

Carcinogenesis

Volumn 26, Issue 7, 2005, Pages 1280-1284

  Cao, Bangwei ^a,b,c   Tian, Xiuyun ^a   Li, Yong ^a   Jiang, Pingwei ^c   Ning, Tao ^a   Xing, Haiping ^d   Zhao, Yiqiang ^a,b   Zhang, Chunfeng ^e   Shi, Xiaotian ^d   Chen, Dafang ^e   Shen, Yan ^b,f   Ke, Yang ^a,b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CHINESE NATIONAL HUMAN GENOME CENTER AT SHANGHAI   (China)

^c First People's Hospital of Xuzhou   (China)

^d Anyang Tumor Hospital   (China)

^e PEKING UNIVERSITY   (China)

^f INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMINE; ISOLEUCINE; LOW MOLECULAR WEIGHT PEPTIDE 7; LYSINE; PROTEASOME; TRASPORTER WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG; VIRUS DNA; DNA; LMP7 PROTEIN; MULTIENZYME COMPLEX;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CHINA; CODON; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA EXTRACTION; DNA POLYMORPHISM; EPITHELIUM CELL; ESOPHAGUS CARCINOMA; ESOPHAGUS MUCOSA; FEMALE; GENOTYPE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; HUMAN CELL; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK FACTOR; VERRUCA VULGARIS; WART VIRUS; CARCINOMA; ESOPHAGUS TUMOR; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; INCIDENCE; MIDDLE AGED; VIROLOGY; VIRUS INFECTION;

ADULT; CARCINOMA; CHINA; DNA; ESOPHAGEAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIENZYME COMPLEXES; PAPILLOMAVIRUS INFECTIONS; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 22844445950     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi071     Document Type: Article

References (34)

1. Chang,F., Syrjanen,S., Wang,L. and Syrjanen,K. (1992) Infectious agents in the etiology of esophageal cancer. Gastroenterology, 103, 1336-1348.
2. Enzinger,P.C. and Mayer,R.J. (2003) Esophageal cancer. N. Engl. J. Med., 349, 2241-2252.
3. Sur,M. and Cooper,K. (1998) The role of the human papilloma virus in esophageal cancer. Pathology, 30, 348-354.
4. Syrjanen,K.J. (2002) HPV infections and esophageal cancer. J. Clin. Pathol., 55, 721-728.
5. Heemels,M.T. and Ploegh,H. (1995) Generation, translocation and presentation of MHC class I-restricted peptides. Annu. Rev. Biochem. 64, 463-491.
6. Driscoll,J., Brown,M.G., Finley,D. and Monaco,J.J. (1993) MHC-linked LMP gene products specifically alter peptidase activities of the proteasome. Nature, 365, 262-264.
7. Gaczynska,M., Rock,K.L. and Goldberg,A.L. (1993) Gamma-interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature, 365, 264-267.
8. Neefjes,J.J., Momburg,F. and Hammerling,G.J. (1993) Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. Science, 261, 769-771.
9. Shepherd,J.C., Schumacher,T.N., Ashton-Rickardt,P.G., Imaeda,S., Ploegh,H.L., Janeway,C.A. and Tonegawa,S. (1993) TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell, 74, 577-584.
10. Cromme,F.V., Airey,J., Heemels,M.T., Ploegh,H.L., Keating,P.J., Stern,P.L., Meijer,C.J. and Walboomers,J.M. (1994) Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J. Exp. Med., 179, 335-340.
11. Maeurer,M.J., Martin,D.M., Storkus,W.J. and Lotze,M.T. (1995) TCR usage in CTLs recognizing melanoma/melanocyte antigens. Immunol. Today, 16, 603-604.
12. Seliger,B., Hohne,A., Knuth,A., Bernhard,H., Ehring,B., Tampe,R. and Huber,C. (1996) Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. Clin. Cancer. Res., 2, 1427-1433.
13. Seliger,B., Maeurer,M.J. and Ferrone,S. (1997) TAP off - tumors on. Immunol. Today, 18, 292-299.
14. Li,T., Lu,Z.M., Chen,K.N., Guo,M., Xing,H.P., Mei,Q., Yang,H.H., Lechner,J.F. and Ke,Y. (2001) Human papillomavirus type 16 is an important infectious factor in the high incidence of esophageal cancer in Anyang area of China. Carcinogenesis, 22, 929-934.
15. Nindl,I., Meyer,T., Schmook,T., Ulrich,C., Ridder,R., Audring,H., Sterry,W. and Stockfleth,E. (2004) Human papillomavirus and over-expression of P16INK4a in nonmelanoma skin cancer. Dermatol. Surg., 30, 409-414.
16. + primer systems. J. Clin. Microbiol., 35 1304-1310.
17. Walboomers,J.M., Jacobs,M.V., Manos,M.M., Bosch,F.X., Kummer,J.A., Shah,K.V., Snijders,P.J., Peto,J., Meijer,C.J. and Munoz,N. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol., 189, 12-19.
18. Stephens,M., Smith,N.J. and Donnelly,P. (2001) A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68, 978-989.
19. Colonna,M., Bresnahan,M., Bahram,S., Strominger,J.L. and Spies,T. (1992) Allelic variants of the human putative peptide transporter involved in antigen processing. Proc. Natl Acad. Sci. USA, 89, 3932-3936.
20. Vargas-Alarcon,G., Gamboa,R., Vergara,Y., Rodriguez-Zepeda,J.M., delaPena,A., Izaguirre,R., Zuniga,J., Ruiz-Morales,J.A. and Granados,J. (2002) LMP2 and LMP2 gene polymorphism in Mexican populations: Mestizos and Amerindians. Genes. Immun., 3, 373-377.
21. Witkowska-Tobola,A.M., Szczerkowska-Dobosz,A., Nedoszytko,B. and Roszkiewicz,J. (2004) Polymorphism of the TAP1 gene in Polish patients with Psoriasis vulgaris. J. Appl. Genet., 45, 391-393.
22. Bosch,F.X., Lorincz,A., Munoz,N., Meijer,C.J. and Shah,K.V. (2002) The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol., 55, 244-265.
23. zur-Hausen,H. (2000) Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer. Inst., 92, 690-698.
24. Lajoie,J., Zijenah,L.S., Faucher,M.C., Ward,B.J., Roger,M. and ZVITAMBO Study Group. (2003) Novel TAP1 polymorphisms in indigenous Zimbabweans: their potential implications on TAP function and in human diseases. Hum. Immunol., 64, 823-829.
25. Lajoie,J., Zijenah,L.S., Faucher,M.C., Ward,B.J., Roger,M. and ZVITAMBO Study Group. (2003) New transporter associated with antigen processing (TAP-2) polymorphisms in the Shona people of Zimbabwe. Hum. Immunol. 64, 733-740.
26. Seliger,B., Maeurer,M.J. and Ferrone,S. (2000) Antigen-processing machinery breakdown and tumor growth. Immunol. Today, 9, 455-464.
27. Seliger,B., Bock,M., Ritz,U. and Huber,C. (2002) High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. Int. J. Oncol., 20, 349-353.
28. Gostout,B.S., Poland,G.A., Calhoun,E.S., Sohni,Y.R., Giuntoli,R.L. II, McGovern,R.M., Sloan,J.A., Cha,S.S. and Persing,D.H. (2003) TAP1, TAP2 and HLA-DR2 alleles are predictors of cervical cancer risk. Gynecol. Oncol., 88, 326-332.
29. Johnsen,A.K., France,J., Nagy,N., Askew,D., Abdul-Karim,F.W., Gerson,S.L., Sy,M.S. and Harding,C.V. (2001) Systemic deficits in transporter for antigen presentation (TAP)-1 or proteasome subunit LMP2 have little or no effect on tumor incidence. Int. J. Cancer, 91 366-372.
30. McCluskey,J., Rossjohn,J. and Purcell,A.W. (2004) TAP genes and immunity. Curr. Opin. Immunol., 16, 651-659.
31. Obst,R., Armandola,E.A., Nijenhuis,M., Momburg,F. and Hammerling,G.J. (1995) TAP polymorphism does not influence transport of peptide variants in mice and humans. Eur. J. Immunol., 25, 2170-2176.
32. Quadri,S.A. and Singal,D.P. (1998) Peptide transport in human lymphoblastoid and tumor cells: Effect of transporter associated with antigen presentation (TAP) polymorphism. Immunol. Lett., 61, 25-31.
33. Daniel,S., Caillat-Zucman,S., Hammer,J., Bach,J.F. and van Endert,P.M. (1997) Absence of functional relevance of human transporter associated with antigen processing polymorphism for peptide selection. J. Immunol., 159, 2350-2357.
34. Sugimoto,Y., Kuzushita,N., Takehara,T. et al. (2002) A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C. J. Viral. Hepat., 9, 377-384.